Holen Sie sich die Stockscreener-App
4.02
1.23%
-0.05
Schlusskurs vom Vortag:
$4.07
Offen:
$4.08
24-Stunden-Volumen:
2.33M
Relative Volume:
1.45
Marktkapitalisierung:
$399.78M
Einnahmen:
$98.99M
Nettoeinkommen (Verlust:
$-197.98M
KGV:
-2.0083
EPS:
-2.0017
Netto-Cashflow:
$-175.32M
1W Leistung:
-4.96%
1M Leistung:
-3.48%
6M Leistung:
-50.86%
1J Leistung:
-60.24%
1-Tages-Spanne:
$3.8101
$4.08
1-Wochen-Bereich:
$3.8101
$4.27
52-Wochen-Spanne:
$3.8101
$13.15
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
4.02 | 399.78M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Northland Capital | Outperform |
| 2025-11-04 | Fortgesetzt | Roth Capital | Buy |
| 2025-09-04 | Eingeleitet | Roth Capital | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Form 4 ARS Pharmaceuticals Inc For: 12 October By Investing.com - Investing.com Canada
Form 4 ARS Pharmaceuticals Inc For: 12 October By Investing.com - Investing.com South Africa
A stock option with a $4.12 exercise price goes to ARS Pharmaceuticals (SPRY) CEO Donn Casale. - Stock Titan
ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role - GlobeNewswire Inc.
Officer Eric Karas proposes selling 100,000 shares of ARS Pharmaceuticals (SPRY). - Stock Titan
Eric Karas proposes selling 100,000 ARS Pharmaceuticals (SPRY) shares after a $69.8K September sale. - Stock Titan
ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Tigo Energy, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmTYGO - GlobeNewswire Inc.
Securities Lawsuit Alert: ARS Pharmaceuticals, Inc. (SPRY)Contact Levi & Korsinsky Before October 5, 2026 - accessnewswire.com
Shareholders of ARS Pharmaceuticals, Inc. (SPRY): Protect Your Rights Before October 5, 2026Contact Levi & Korsinsky - ACCESS Newswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire Inc.
מועד אחרון לתביעה ייצוגית נגד DATAVAULT AI: רוזן, יועץ למשקיעים מהימן, קורא למשקיעי Datavault AI Inc. לשכור ייצוג משפטי לקראת מועד חשוב ב- 5 באוקטובר בתביעה ייצוגית בניירות הערך – DVLT - GlobeNewswire Inc.
מועד אחרון לתביעה ייצוגית נגד ARS PHARMACEUTICALS: רוזן, יועץ למשקיעים מהימן, קורא למשקיעי ARS Pharmaceuticals, Inc. לשכור ייצוג משפטי לקראת מועד אחרון חשוב בתביעה הייצוגית בניירות הערך – SPRY - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY - GlobeNewswire Inc.
ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
AARD IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD - GlobeNewswire Inc.
ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
HDB IMPORTANT DEADLINE: ROSEN, TOP RAKED GLOBAL COUNSEL, Encourages HDFC Bank Limited Investors to Secure Counsel Before Important Deadline in Securities Class ActionHDB - GlobeNewswire Inc.
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action LawsuitInvestors Should Contact SueWallSt - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - globenewswire.com
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
SPRY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Robbins LLP Reminds Investors of the Securities Fraud Class - GlobeNewswire
Richard Lowenthal to sell 35,000 ARS Pharma (SPRY) shares - Stock Titan
ARS Pharmaceuticals (SPRY) officer sold $250K in stock and plans more - Stock Titan
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Morningstar
Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals - GlobeNewswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
ARS Pharma at Cantor Global Healthcare: provider push lifts neffy - Investing.com India
ARS Pharma at Cantor Global Healthcare: provider push lifts neffy By Investing.com - Investing.com Canada
SueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026SPRY - PR Newswire
ARS Pharmaceuticals (SPRY) Short Interest & Short Float | Updated Sep 2026 $SPRY - MarketBeat
רוזן, יועץ למשקיעים מהימן, קורא למשקיעי ARS Pharmaceuticals, Inc. לשכור ייצוג משפטי לקראת מועד אחרון חשוב בתביעה הייצוגית בניירות הערך – SPRY - GlobeNewswire Inc.
SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pha - The National Law Review
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities LawsuitContact Levi & Korsinsky - PR Newswire
Kaplan Fox Deadline Alert: ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Have Until October 5, 2026 to Seek a Lead Plaintiff Role - newmediawire.com
Kaplan Fox Deadline Alert: ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Have Until October 5, 2026 to Seek a Lead Plaintiff Role - Barchart.com
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ARS Pharmaceuticals (NasdaqGM:SPRY) Stock Forecast & Analyst Predictions - Simply Wall Street
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Conway Daily Sun
ROSEN, A TOP RANKED LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSPRY - ACCESS Newswire
Another ARS Pharma (NASDAQ: SPRY) insider stock sale is coming, with the size now disclosed - Stock Titan
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - globenewswire.com
Kaplan Fox Continues to Remind ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors of the Lead Plaintiff Deadline on October 5, 2026 - NewMediaWire
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ars Pharmaceuticals Inc-Aktie (SPRY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ERIC KARAS | Officer |
Sep 30 '26 |
Proposed Sale |
4.32 |
100,000 |
431,560 |
0 |
| RICHARD LOWENTHAL | Officer |
Sep 11 '26 |
Proposed Sale |
5.06 |
35,000 |
176,995 |
0 |
| ERIC KARAS | Officer |
Sep 11 '26 |
Proposed Sale |
4.96 |
14,064 |
69,762 |
0 |
| RICHARD LOWENTHAL | Officer |
Sep 04 '26 |
Proposed Sale |
5.61 |
75,000 |
421,058 |
0 |
| RICHARD LOWENTHAL | Officer |
Sep 03 '26 |
Proposed Sale |
5.84 |
19,805 |
115,564 |
0 |
| RICHARD LOWENTHAL | Officer |
Sep 02 '26 |
Proposed Sale |
5.95 |
840 |
5,000 |
0 |
| SARINA TANIMOTO | Officer |
Sep 01 '26 |
Proposed Sale |
6.01 |
45,388 |
272,850 |
0 |
| SARINA TANIMOTO | Officer |
Aug 31 '26 |
Proposed Sale |
5.82 |
63,289 |
368,099 |
0 |
| RICHARD LOWENTHAL | Officer |
Aug 20 '26 |
Proposed Sale |
5.93 |
25,000 |
148,160 |
0 |
| SARINA TANIMOTO | Officer |
Aug 20 '26 |
Proposed Sale |
5.92 |
25,000 |
147,970 |
0 |
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):